Skip to main content

Table 1 Characteristics of healthy controls (HC) and patients with systemic lupus erythematosus (SLE)

From: Enhanced IFN-α production is associated with increased TLR7 retention in the lysosomes of palasmacytoid dendritic cells in systemic lupus erythematosus

  HC SLE
Number 45 71
Female/male, n 41/4 66/5
Age, years 36.0 (21.0–56.0) 36.0 (22.0–60.0)
Disease duration, years   7.0 (0.0–31.0)
Anti-DNA antibody (IU/mL)   3.5 (2.0–300.0)
C3 (mg/dL)   67.0 (9.0–195.0)
CH50 (U/mL)   29.4 (2.0–78.1)
SLEDAI score   4.0 (2.0–34.4)
 SLEDAI < 5, n   41
 SLEDAI ≥ 5, n   30
Disease
 Glomerulonephritis, n   37
 Arthritis, n   11
 Neuropsychiatric SLE, n   8
 Pancytopenia, n   6
 Lupus enteritis, n   5
 Cutaneous lupus erythematosus, n   3
 Pneumonitis, n   1
Medications
 Medication naïve, n   10
 Prednisone, n   57
 Prednisone dose (mg/day)   7.0 (2.0–45.0)
 Immunosuppressive agenta, n   19
  1. Values are number or median (interquartile range)
  2. SLEDAI Systemic Lupus Erythematosus Disease Activity Index 2000
  3. aAzathioprine, mizoribine, mycophenolate mofetil, tacrolimus